Ashwin Patel, MD
Internal Medicine · Phoenix, AZNPI 1811984255
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AstraZeneca at 31.1% of the total. 2025 is the largest year on record at $660, 2.5 times the $262 reported in 2019.
Across 108 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$709
- Lilly USA, LLC$185
- Mannkind Corporation$170
- Amgen$156
- AbbVie$117
- Boehringer Ingelheim$98
- plus $847 from 20 others
What the payments were for
- Food & beverage$2,17395%
- Education$502%
- Gifts$593%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $709 |
| Lilly USA, LLC | 11 | $185 |
| Mannkind Corporation | 8 | $170 |
| Amgen | 9 | $156 |
| AbbVie(2 entities) | 6 | $117 |
| Boehringer Ingelheim | 4 | $98 |
| Intuitive Surgical | 1 | $95 |
| Pfizer | 4 | $85 |
| Currax Pharmaceuticals LLC | 4 | $82 |
| Abbott | 3 | $68 |
| Merck | 4 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Johnson & Johnson | 2 | $48 |
| Novo Nordisk | 3 | $47 |
| Novartis | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Boston Scientific | 1 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $29 |
| Corcept Therapeutics | 1 | $25 |
| Phadia US Inc. | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Bayer | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Qiagen, LLC | 1 | $17 |
How this compares
$2,282 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 97 | $92,196 |
| JanuviaSitagliptin Phosphate | 79 | $73,928 |
| EliquisApixaban | 59 | $63,655 |
| JardianceEmpagliflozin | 63 | $59,382 |
| FarxigaDapagliflozin Propanediol | 48 | $34,141 |
| XareltoRivaroxaban | 20 | $25,478 |
| TrulicityDulaglutide | 19 | $23,753 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $21,075 |
| LinzessLinaclotide | 19 | $11,155 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $9,988 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $6,886 |
| Novolog FlexpenInsulin Aspart | 22 | $5,263 |
| Atorvastatin Calcium | 437 | $3,779 |
| Omeprazole | 131 | $2,804 |
| Colchicine | 40 | $2,589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $47 | $92,19697 claims |
| MerckJanuvia | $63 | $73,92879 claims |
| PfizerEliquis | $85 | $63,65559 claims |
| Boehringer IngelheimJardiance | $98 | $59,38263 claims |
| AstraZenecaFarxiga | $709 | $34,14148 claims |
| Johnson & JohnsonXarelto | $48 | $25,47820 claims |
| Lilly USA, LLCTrulicity | $185 | $23,75319 claims |
| AbbVieLinzess, Synthroid | $117 | $12,35230 claims |
| GSKTrelegy Ellipta | $18 | $6,88612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Phoenix
- Frank LovecchioPhoenix$911K
- Nasser HajaigPhoenix$687K
- Kelly KrohnPhoenix$262K
- Paul StanderPhoenix$222K
- Howard GrossmanPhoenix$131K
- Nafis Shamsid-DeenPhoenix$115K
- Shishir MurarkaPhoenix$79K
- Mark WongPhoenix$71K
- Geoffrey OrmePhoenix$27K
- Roberto RuizPhoenix$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.